Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea
· Delayed Price · Currency is KRW 4,840.00
-45.00 (-0.92%)
At close: Jun 27, 2025, 3:30 PM KST
Kyongbo Pharmaceutical Revenue
Kyongbo Pharmaceutical had revenue of 60.59B KRW in the quarter ending March 31, 2025, a decrease of -3.21%. This brings the company's revenue in the last twelve months to 236.54B, up 2.40% year-over-year. In the year 2024, Kyongbo Pharmaceutical had annual revenue of 238.56B with 10.26% growth.
Revenue (ttm)
236.54B
Revenue Growth
+2.40%
P/S Ratio
0.50
Revenue / Employee
n/a
Employees
n/a
Market Cap
119.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 238.56B | 22.20B | 10.26% |
| Dec 31, 2023 | 216.36B | 20.09B | 10.24% |
| Dec 31, 2022 | 196.26B | 25.61B | 15.00% |
| Dec 31, 2021 | 170.66B | -44.63B | -20.73% |
| Dec 31, 2020 | 215.29B | 23.58B | 12.30% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |
| Peptron | 4.30B |